Summary Infection has long been suspected as a possible factor in the aetiology of leukaemia and lymphoma. If seasonal variation in the onset of disease could be shown in any of the diagnostic subgroups of leukaemia or tymphoma, this would provide supportive evidence of an aetiology linked to exposure to infection. All cases in the Manchester Children's Tumour Registry (aged 0-14 years at diagnosis) with acute tymphoblastic leukaemia (ALL), acute non-lymphocytic leukaemia (ANLL), Hodgkin's disease (HD) or non-Hodgkin Iymphoma (NHL) between 1 January 1954 and 31 December 1996 were included in an analysis of seasonal variation in the month of first symptom and the month of diagnosis. Cases of common acute lymphoblastic leukaemia (c-ALL) diagnosed from 1979 onwards were also analysed separately. The groups considered for analysis were: all cases of ALL (n = 1070), ALL diagnosed between 18 and 95 months of age (n = 730), ALL diagnosed over 95 months of age (n = 266), c-ALL (n = 309), ANLL (n = 244), all infant acute leukaemias (ALL and ANLL under 18 months: n = 107), HD (n = 166) and NHL (n = 189). Using the Edwards method, both c-ALL and HD demonstrated significant seasonal variation (P = 0.037 and 0.001 respectively) in date of first symptom, with peaks occurring in November and December respectively. Using this method, no indication of seasonal variation was found in the other diagnostic groups for date of first symptom or in any of the diagnostic groups for date of diagnosis. For comparison with a previous study, a further analysis based on date of diagnosis for all ALL cases, using summer-winter ratios.
identified. Evidence for the involvement of infections in certain lymphomas is more direct. Notably. Epstein-Barr virus (EBV) appears to be aetiologically linked to Burkitt's lvmphoma (Day et al. 1985 ) and Hodgkin's disease (Hummell et al. 1992 : Armstrong et al. 1993 : Kahn and Coates. 1994 : Weinreb et al. 1996 .
If infections are involved in the aetioloay of childhood leukaemia and lymphoma. some seasonal pattern of onset might be expected.
Past studies into seasonal variation of date of onset of acute leukaemia and lymphoma have been limited by the relatively poor quality and quantity of data. or inadequate statistical testinc of the apparent peak in incidence. This has given rise to a number of conflicting reports as to wihether a peak in incidence exists and. if so.
when it occurs (Lambin and Gerard. 1934 : Forkner. 1938 : Scanu. 1954 : Hayes. 1961 : Lee. 1962 : Fraumeni. 1963 : Bjelke. 1964 : Gunz and Spears. 1968: Walker and Van Noord. 1982 Correspondence to: JM Birch prox iding possible support for an infectious aetiology for this condition (Badrinath et al. 1997 ).
Given the current interest in the possible aetiological role of infections. we have performed a comprehensix e study of studied seasonal variation The Manchester Children's Tumour Registrx (MCTR) (Blair and Birch. 1994 ) has high-qualits populationbased data in sufficient quantity to enable the use of powerful statistical techniques. We therefore hoped to achieve a more reliable assessment of anv seasonal fluctuations in onset.
MATERIALS AND METHODS
Cases for the studv w-ere ascertained from the MCTR. All instances of malignant disease and certain other neoplastic conditions (patients aged 0-14 years) (Birch. 1988) .
Final diagnoses were coded using both the topographv and morphology codes from the second edition of the International Classification of Diseases for Oncology (ICD-O) (World Health Organization. 1990 ) and were then allocated to diagnostic groups using a modification of the classification scheme based on ICD-O and developed for childhood cancer (Birch and Marsden. 1987 Walter (1994) .
The Kruskall-Wallis test was used to identify differences in median lag times. where lag time is defined as the number of whole weeks between the recorded date of first symptom and the date of diagnosis. To repeat the analysis by Badrinath et al ( 1997) .
the ratio of summer (May-October) to winter (November-April) cases was calculated, together with the 95% confidence interval for the ratio. In all analysis. a P-value of less than 0.05 was taken to be statistically significant. In total. the number of cases identified for this stud) was 1669. which comprised 1070 ALL (including 309 cases of defined c-ALL diagnosed since 1979). 244 ANLL. 166 HI and 189 NHL. Diagnosis was based on the histological examination of bone marrow for 92% of the ALL cases. on blood smears for 6% and, for the remainder. on examination of cerebrospinal fluid and investigation at post-mortem. For ANLL. 90%7 were diagnosed through bone marrow investigation. 9%7 through blood smears and the remainder thdrough investigation at post-mortem. The diagnosis of HD was made through primary-site biopsy for 99% of the cases and for 1%7 by investigation at postmortem. Fmally. for NHL. 89%-of cases were diagnosed through primary-site biopsy. 10% through investigation at post-mortem and the remainder through haeematological examination. Therefore. detailed diagnostic information based on bone marrow. histology or cytology was available for 100%7 of cases. Tables 1 and 2 show the number of cases by month of first symptom and month of diagnosis respectively. The results of the statistical tests for heterogeneity and periodicity in month of first symptom and month of diagnosis are shown in there was a highly significant departure from the uniform distribution (P = 0.002), providing strong evidence of a seasonal effect. Applying Edwards' method to detect a sinusoidal curve within a 12-month period. we found significant results in the c-ALL and HD groups (P = 0.037 and 0.001 respectively). For the c-ALL group, the curve had a significant peak in November, with an amplitude of 21.1% (Figure 1 ) and for the HD group the curve had a significant peak in December, with an amplitude of 41.0% (Figure 2) .
RESULTS

Results based on month of diagnosis
Repeating the above techniques on the month of diagnosis. the heterogeneity test did not detect any departures from the uniform distribution in any of the diagnostic groups. Likewise. the Lag time between first symptom and diagnosis Having found a significant seasonal effect in date of first symptom for c-ALL and Hodgkin's disease, we might have expected this effect to follow on for date of diagnosis also. As this was not the case. there may be differences in lag time at different times of the year. However. testing for differences between months for lag times in the ALL. c-ALL and Hodgkin's disease patient groups showed no significant differences (Table 4) .
DISCUSSION
In order to assess seasonality accurately, it is essential that case ascertainment is unbiased and has a high level of completeness. together with consistent and accurate diagnoses throughout the study period. It has been estimated that the level of completeness achieved by the MCTR during the first 20 years of operation was between 95% and 98% (Leck et al. 1976) . and ad hoc checks have indicated that this has been sustained. The MCTR maintains a collection of detailed clinical records and pathology material so that diagnoses can be reviewed when appropriate. Accuracy and consistency of diagnostic classification are thus ensured. The MCTR therefore provides a dataset that fulfils all the necessary criteria There were marked differences in seasonal pattems according to diagnostic group. For ANLL and NHL. our results have shown no apparent seasonal variation in date of first symptom or date of diagnosis. This could indicate that infections do not play a role in the aetiology of these diseases. However. the involvement of infections cannot be ruled out and longer, more variable latent periods may obscure any seasonal trends. Other key factors, such as heterogeneity. within the disease or causative agents that do not behave in an epidemic fashion could also account for the lack of seasonal trends in disease onset.
In contrast, very striking seasonal variation in date of first symptom was found in HD. producing a highly significant peak in December. with an amplitude of 41.0%. A common virus has long been suspected as being a key factor in the aetiology of childhood HD (Mueller, 1991) . More recent evidence suggests a link between Epstein-Barr virus (EBV) and HD in children and adults (Hummel et al. 1992; Armstrong et al. 1993: Khan and Coates, 1994) . A recent study (Weinreb et al. 1996) of the EBV status in childhood HD patients in different countries found that 50% of the UK cases studied were positive for the latent membrane protein 1 (LMP 1). with 100% of the 56 cases from Kenya positive for LMP 1. Our results add to the evidence suggesting a viral or other infective basis for the cause of this disease.
British Joumal of Cancer (1998) 78(1) Significant seasonal variation for HD was only found in date of first symptom and not in date of diagnosis, suggesting that date of first symptom more closely reflects the event that precipitates clinical onset of disease than date of diagnosis. Because of the distinctive presenting symptoms of HD, the date of first symptom should provide a reliable indication of disease onset. However, there can be a considerable lag time between date of first symptom and date of diagnosis. For example, enlarged nodes may not always be recognized as neoplastic and may be initially treate as infection.
This variation in date of diagnosis relative to onset of symptoms may be enough to remove any seasonal pattern visible at the earlier point in time.
A much more complex pattern emerged for ALL than for other diagnostic groups described above. It is known that ALL comprises a number of diagnostic subgroups characterized by immunophenotypic markers with associated cytogenetic changes. Aetiological factors may be different for the various subgroups, and studies of causation of childhood leukaemia should attempt to address this issue. The MCTR includes population-based data on ALL by immunophenotype from 1979 onwards. Among the immunophenotyped cases, 74.8% of c-ALL were aged 18-95 months at diagnosis and 86.5% of this age group were c-ALL.
Greaves hypothesis, which relates to the pattem and timing of infections, is specific for c-ALL and, to try to assess seasonal variations in c-ALL for the whole time period under study, we analysed the age group 18-95 months.
For 1979 onwards, we were able to analyse c-ALL regardless of age at diagnosis. For defined cases of c-ALL, we observed a significant peak in November, with an amplitude of 21.1 %, based on date of first symptom. However, no significant result was found using date of diagnosis. The reason for the difference between the two sets of results could be a result of variation in lag time. This was tested and, although no significant differences were found between monthly median lag times, a minor variation would be enough to conceal an underlying sinusoidal curve. The fact that we found a significant seasonal trend in first symptom for c-ALL could imply a relatively short latent period between exposure to the 'precipitating factor' and onset of first symptom. If this were not the case, the likely variation in latent period would almost certainly cloud any trend associated with the initial event. The idea of a short latent period is consistent with the Greaves' model. Tlere was no equivalent peak based on date of first symptom for the age group 18-95 months over the study period. This apparent discrepancy is probably explained by the proportion of non c-ALL cases in this group and the fact that a proportion of c-ALL cases occurs at other ages. We have shown that the incidence of ALL inreased dunng the study period and this appears to be due to c-ALL (Blair and Birch, 1994; Westerbeek et al, submitted) . Therefore, the proportion of c-ALL may have been lower during the earlier years covered by the study. These factors suggest that the November peak based on date of first symptom is specific for c-ALL and is not present in other subtypes.
The results of the Edwards' test in ALL based on date of diagnosis showed peaks of borderline significance in July, for the age group 0-179 months (P = 0.095), and in June, for the age group 18-95 months (P = 0.072). These findings are consistent with the recent report by Badrinath and colleagues (1997) in which a roader measure of seasonal variation was used. Splitting the year into two periods, summer (May-October) and winter (November-April), they found that the ratio of childhood (0-14 years inclusive) ALL cases diagnosed in summer to those diagnsed in winter was 1.40 (P ' 0.01). Repeating this analysis for our study cases, we found a lower summer-winter ratio of 1.16 (Cimino et al, 1997) . In these cases, date of diagnosis may be an adequate marker of biological onset of disease, reflecting the very short latent period. Taken together, the set of results on ALL may indicate that there could be a number of underlying seasonal patterns contained within this diverse diagnostic group. For c-ALL, specifically, we were able to demonstrate a winter peak associated with onset of disease-related symptoms, which clearly emphasizes the need to consider the disease subgroups independently. In the MCTR series at present, there are insufficient numbers of cases with immunophenotypes other than c-ALL to enable a true assessment of seasonality. The complexity of seasonal trends in ALL will only be resolved when full information on diagnostic subtype is available for a large enough series to permit detailed analyses.
Inconsistencies between results of previously published studies may be due to differences in definition of diagnostic groups, differences in reference dates used or genuine regional, national and international differences (Harris et al, 1987) . In this context, if various subtypes of ALL exhibit different seasonal trends in onset, variations in the case-mix between populations might account for at least some of the inconsistencies between studies.
In summary, the results of this study strengthen the case for an association between childhood acute lymphoblastic leukaemia (in particular c-ALL), Hodgkin's disease and response to an infective agent, and demonstrate the need for further molecular and immunohistochemical definition of diagnostic groups to be used in future studies of childhood leukaemia and lymphoma aetiology.
